Theresa E Crofts

Learn More
PURPOSE For patients with small-cell lung cancer (SCLC), further chemotherapy is routinely considered at relapse after first-line therapy. However, proof of clinical benefit has not been documented. PATIENTS AND METHODS This study randomly assigned patients with relapsed SCLC not considered as candidates for standard intravenous therapy to best supportive(More)
PURPOSE Inactivation of the von Hippel-Lindau gene in clear-cell renal cell carcinomas (RCC) leads to overexpression of hypoxia inducible factor, a transcription factor regulating vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) gene expression. Pazopanib, an angiogenesis inhibitor targeting VEGF receptor, PDGF receptor,(More)
UNLABELLED Noncardiac chest pain (NCCP) presents as a frequent diagnostic challenge, with patients tending to use a disproportionate level of health care resources. Gastroesophageal reflux disease (GERD) is the most frequent cause of NCCP. GOALS To test the efficacy of a potent acid-suppressing agent as a diagnostic test in the evaluation of NCCP and to(More)
PURPOSE This open-label, randomized, multicenter phase III study compared oral topotecan/intravenous cisplatin (TC) with intravenous (IV) etoposide/cisplatin (PE) in patients with untreated extensive-disease small-cell lung cancer (ED-SCLC). PATIENTS AND METHODS A total of 784 patients were randomly assigned to either oral topotecan 1.7 mg/m2/d x 5 with(More)
9721 Background:Tumour response is the major surrogate by which new cancer therapies are evaluated. However, demonstrating a consistent relationship between response and survival has been problematic, and establishing the clinical benefit associated with prolonged stabilisation of disease has been particularly elusive. METHODS In order to establish a(More)
INTRODUCTION Measurement of the upper limit of vulnerability (ULV) with monophasic T wave shocks has been proposed as a patient-specific measurement of defibrillation efficacy that results in fewer episodes of ventricular fibrillation (VF) than measurement of a defibrillation efficacy curve. METHODS AND RESULTS We sought to determine the magnitude of(More)
7046 Background: IV topotecan is an established therapy in relapsed, "sensitive" SCLC. Oral and IV topotecan have similar activity and tolerability. Phase II data in combination with cisplatin as well as data from Noda et al provided the rationale for this study. METHODS Chemotherapy-naïve patients with ED-SCLC and performance status ECOG 0, 1, or 2(More)
  • 1